Aviso Financial Inc. Sells 2,170 Shares of Danaher Corporation $DHR

Aviso Financial Inc. lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 6.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,357 shares of the conglomerate’s stock after selling 2,170 shares during the quarter. Aviso Financial Inc.’s holdings in Danaher were worth $5,799,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after buying an additional 788,499 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Geode Capital Management LLC increased its holdings in Danaher by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after purchasing an additional 81,670 shares in the last quarter. Generation Investment Management LLP raised its stake in shares of Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after purchasing an additional 1,787,522 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Danaher by 4.0% in the second quarter. Franklin Resources Inc. now owns 4,822,442 shares of the conglomerate’s stock valued at $952,625,000 after purchasing an additional 186,357 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DHR shares. Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. increased their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Cowen reissued a “buy” rating on shares of Danaher in a research report on Wednesday, October 22nd. Finally, Evercore ISI upped their price objective on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $243.39.

Danaher Stock Performance

Shares of DHR opened at $227.05 on Tuesday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock’s fifty day moving average price is $209.36 and its two-hundred day moving average price is $202.34. The firm has a market cap of $160.38 billion, a PE ratio of 46.81, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.71 EPS. On average, equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Insider Buying and Selling

In related news, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.